论文部分内容阅读
目的:探讨分析瑞舒伐他汀治疗2型糖尿病合并血脂异常患者的疗效。方法:从2013年8月到2016年1月,选取我院诊治的140例2型糖尿病合并血脂异常患者进行回顾性分析。在常规降糖基础上,随机分为观察组70例和对照组70例,观察组给予瑞舒伐他汀10mg/d,治疗8周,观察分析治疗前后血脂四项(TG、TC、HDL-C、LDL-C)、超敏C反应蛋白(hs-CRP)的变化及不良反应情况。结果:治疗组TC、TG、LDLC、hs-CRP水平较治疗前相比显著下降(P<0.01),均低于对照组(P<0.01);治疗组HDL-C水平较治疗前显著升高(P<0.01)。结论:瑞舒伐他汀可降低2型糖尿病合并血脂异常患者hs-CRP及血脂水平,疗效显著。
Objective: To investigate the efficacy of rosuvastatin in the treatment of type 2 diabetes with dyslipidemia. Methods: From August 2013 to January 2016, 140 patients with type 2 diabetes mellitus and dyslipidemia selected from our hospital were retrospectively analyzed. On the basis of routine hypoglycemic, the patients were randomly divided into observation group (70 cases) and control group (70 cases). The observation group was given rosuvastatin 10 mg / d for 8 weeks. The levels of TG, TC and HDL- , LDL-C), hs-CRP and adverse reactions. Results: The levels of TC, TG, LDLC and hs-CRP in the treatment group were significantly lower than those before treatment (P <0.01), and were lower than those in the control group (P <0.01). The levels of HDL-C in the treatment group were significantly higher than those before treatment (P <0.01). Conclusion: Rosuvastatin can reduce hs-CRP and blood lipid levels in type 2 diabetic patients with dyslipidemia.